As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...
7h
GEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver Diseases
Gemma Biotherapeutics ("GEMMABio"), a clinical-stage, global, genetic medicines company, today announced that it has been awarded funding by the Advanced Research Projects Agency for Health (ARPA-H).
A trio of common amino acids may hold the key to unlocking far more powerful gene therapies. Researchers found that adding them to lipid nanoparticles can boost mRNA delivery up to 20-fold and push ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results